



STATE OF WEST VIRGINIA  
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin  
Governor

Bureau for Medical Services  
Pharmacy Services  
350 Capitol Street – Room 251  
Charleston, West Virginia 25301-3706  
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling  
Cabinet Secretary

**Pharmaceutical and Therapeutics Committee**  
**October 22, 2014**

Location: Charleston Civic Center  
200 Civic Center Drive  
Charleston, WV 25301-2016

**MINUTES**

**Members Present:**

Jeffrey V. Ashley, M.D.  
Elizabeth Baldwin, RN, MSN, PNP, APRN-BC  
Scott Brown, R.Ph.  
Rodney L. Fink, D.O.  
Michael Grome, PA-C  
Bradley Henry, M.D.  
Tom Kines, R.Ph.  
Steven R. Matulis, M.D, Chairman  
Amelia McPeak, D.O.  
Harriet Nottingham, R.Ph.  
Robert Stanton, Pharm.D., Vice Chairman

**Members Not Present:**

David Avery, M.D.

**DHHR/BMS Staff Present:**

William Hopkins, Pharmacy Operations Manager  
Brian Thompson, MS, Pharm.D., DUR Coordinator  
Richard D. Sorvig, Administrative Assistant

**Contract Staff/Magellan Rx Management Staff Present:**

Nina Bandali, Pharm.D.  
Giovannino Perri, M.D.

**Other Contract Staff/State Staff Present:**

Julia Rollins, R.Ph., Molina Medicaid Solutions  
Steve Small, R.Ph., MS, Director, Rational Drug  
Therapy Program

## **I. Call to Order**

Dr. Steven Matulis, Chairperson, called the meeting to order at 9:10AM.

## **II. Welcome and Introductions**

All parties seated at the table introduced themselves. Mr. William Hopkins explained the public comment process, including the time limit of three minutes per product for each speaker. He also stated that Dr. David Avery, Dr. Steven Matulis, and Ms. Harriet Nottingham will be retiring from their service as P&T members. He expressed appreciation and thanked the three members for their time and service. Additionally, he acknowledged Ms. Anita Souder for her 31 years of service to the State as she will also be retiring.

## **III. Housekeeping Items/Updates**

### **A. Approval of the August 27, 2014 Minutes**

Dr. Matulis asked for approval of the minutes from the August 27, 2014 P&T meeting. A motion was made and seconded; the motion carried to approve the minutes as submitted.

### **B. Explanation of Extraction Process**

Dr. Matulis explained the process used in the extraction of classes for voting. Those classes that are extracted are further discussed and voted on individually while the rest of the classes are voted in blocks for approval.

### **C. PDL Compliance/Generic Percent Report Updates**

Dr. Nina Bandali reported the overall PDL compliance for Q2 2014 was 96.8% and the generic utilization rate for Q2 2014 was 82.0%.

## **IV. Magellan Presents Summary of Recommended PDL Changes**

Dr. Bandali presented a summary of Magellan's recommended PDL changes.

## **V. Chairman Calls for First Round of Extractions**

The following classes were named by Committee members for extraction:

- Analgesics, Narcotic – Long-Acting
- Angiotensin Modulators
- Antiparasitics, Topical
- Beta Blockers
- Bladder Relaxant Preparations
- Bone Resorption Suppression and Related Agents
- BPH Treatments
- COPD Agents
- Epinephrine, Self-Injected
- Glucocorticoids, Inhaled
- Hepatitis B Treatments
- Hepatitis C Treatments

- Hypoglycemics, Incretin Mimetics/Enhancers
- Hypoglycemics, SGLT2
- Irritable Bowel Syndrome
- Laxatives and Cathartics
- Lipotropics, Statins
- Neuropathic Pain
- NSAIDs
- Ophthalmics, Anti-Inflammatories-Immunomodulators
- Opiate Dependence Treatments

## **VI. Public Comments**

Nicole Becker, AstraZeneca, spoke in favor of Bydureon

Sejal Patel, Salix, spoke in favor of Moviprep, Uceris, and Xifaxan.

Margaret Wooddell, Mylan, spoke in favor of Epipen.

Jonathan Oliver, Astellas, spoke in favor of Myrbetriq.

Kent Hunter, Pfizer, spoke in favor of of Xeljanz.

Carla McSpadden, Forst/Actavis, spoke in favor of Linzess and Daliresp.

Amber Root, Actelion, spoke in favor of Opsumit.

Shanna Price, Sanofi, spoke in favor of Lantus.

John Kirby, Sanofi, spoke in favor of Genzyme.

Paul Miner, Gilead, spoke in favor of Sovaldi.

Ronnie Depue, Sunovion, spoke in favor of Latuda.

Jake Nicholas, Orexo, spoke in favor of Zubsolv.

Patricia Dubin, pediatrician at the Cystic Fibrosis Foundation, spoke in favor of Pancreatic Enzyme and Inhaled Antibiotics.

Joan Zhong Xue-Zhang, United Therapeutics, spoke in favor of Orenitram.

Jeremy Soule, endocrinologist, spoke in favor of SGLT2 Inhibitors.

Scott Collins, VCG and Associates, spoke on behalf of Silvergate Pharmaceuticals in favor of Epaned.

Catherine Williams, Celgene Corp, spoke in favor of Otezla.

Ndidi Yaucher, Novartis, spoke in favor of Gilenya and Tobi Podhaler.

Andrea Windsheimer, Novo Nordisk, spoke in favor of Victoza.

David Bedich, ParaPRO, spoke in favor of Natroba.

## **VII. Chairman Calls for Second Round of Extractions**

The following classes were named by Committee members during the second round of extractions:

- Antibiotics, Inhaled
- Antipsychotics, Atypical
- Hypoglycemics, Insulin and Related Agents
- Pancreatic Enzymes
- Ulcerative Colitis Agents

### VIII. Motion for All Non-Extracted Categories to be Approved as Proposed

The motion to approve all non-extracted class recommendations as presented by Magellan was made and seconded. A vote was taken and the motion was approved.

### IX. Executive session

The motion was made and seconded to adjourn to executive session for confidential pricing discussion. A vote was taken and the motion was approved at 10:36AM. The meeting resumed at 1:22PM.

### X. Lunch Break

### IX. Extracted Therapeutic Category Reviews/Committee Recommendations

#### A. Analgesics, Narcotic – Long-Acting

Magellan recommended that hydromorphone ER and Xartemis XR be added to non-preferred status. There was further discussion from the members on adding other alternatives due to the rescheduling of hydrocodone combination products. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

<b>ANALGESICS, NARCOTIC LONG ACTING (Non-parenteral)<sup>AP</sup></b>	
fentanyl transdermal	AVINZA (morphine)
morphine ER tablets	BUTRANS* (buprenorphine)
	CONZIP ER (tramadol)
	DOLOPHINE (methadone)
	DURAGESIC (fentanyl)
	EXALGO ER (hydromorphone)
	EMBEDA (morphine/naltrexone)
	<b>hydromorphone ER</b>
	KADIAN (morphine)
	methadone tablet, solution and concentrate**
	methadone solutabs
	morphine ER capsules (generic for Avinza)
	morphine ER capsules (generic for Kadian)
	MS CONTIN (morphine)
	NUCYNTA ER (tapentadol)
	OPANA ER (oxymorphone)
	oxycodone ER**
	OXYCONTIN (oxycodone)
	oxymorphone ER**
	RYZOLT ER (tramadol)
	tramadol ER
	ULTRAM ER (tramadol)
	<b>XARTEMIS XR (oxycodone/ acetaminophen)</b>
	ZOHYDRO ER (hydrocodone)

#### B. Angiotensin Modulators

Magellan recommended that valsartan be moved to non-preferred status and Azor be moved to preferred status. There was some discussion in regards to combination products being more costly than their respective components. A Committee member

suggested taking a closer look at this in future reviews. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

<b>ANGIOTENSIN MODULATORS<sup>AP</sup></b>	
<b>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs)</b>	
BENICAR (olmesartan) DIOVAN (valsartan) irbesartan losartan MICARDIS (telmisartan)	ATACAND (candesartan) AVAPRO (irbesartan) candesartan COZAAR (losartan) EDARBI (azilsartan) eprosartan telmisartan TEVETEN (eprosartan) Valsartan
<b>ARB COMBINATIONS</b>	
AZOR (olmesartan/amlodipine) BENICAR-HCT (olmesartan/HCTZ) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) irbesartan/HCTZ losartan/HCTZ MICARDIS-HCT (telmisartan/HCTZ) valsartan/HCTZ	ATACAND-HCT (candesartan/HCTZ) AVALIDE (irbesartan/HCTZ) candesartan/HCTZ DIOVAN-HCT (valsartan/HCTZ) EDARBYCLOR (azilsartan/chlorthalidone) HYZAAR (losartan/HCTZ) telmisartan/amlodipine telmisartan HCTZ TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/HCTZ) TWINSTA (telmisartan/amlodipine)

### C. Antibiotics, Inhaled

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

<b>ANTIBIOTICS, INHALED</b>	
BETHKIS (tobramycin) TOBI (tobramycin)	CAYSTON (aztreonam) TOBI PODHALER Tobramycin

### D. Antiparasitics, Topical

Magellan recommended that permethrin cream be added with a non-preferred status. A motion was made to accept the recommendations with the addition of Natroba being moved to preferred status. A vote was taken and the motion was approved.

<b>ANTIPARASITICS, TOPICAL<sup>AP</sup></b>	
NATROBA (spinosad) permethrin 1% lotion (OTC) pyrethrins-piperonyl butoxide OTC SKLICE (ivermectin) ULESFIA (benzyl alcohol)	EURAX (crotamiton) LICE EGG REMOVER OTC (benzalkonium chloride) lindane malathion OVIDE (malathion) permethrin 5% cream spinosad

## E. Antipsychotics, Atypical

Magellan recommended that Risperdal Consta be moved to preferred status. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

ANTIPSYCHOTICS, ATYPICAL	
SINGLE INGREDIENT	
ABILIFY (aripiprazole) <sup>AP</sup> *	ADASUVE (loxapine)
ABILIFY MAINTENA (aripiprazole) <sup>**CL</sup>	clozapine ODT
clozapine	CLOZARIL (clozapine)
FANAPT (iloperidone) <sup>AP</sup>	FANAPT TITRATION PACK (iloperidone)
INVEGA SUSTENNA (paliperidone) <sup>**CL</sup>	FAZACLO (clozapine)
LATUDA (lurasidone) <sup>AP</sup>	GEODON (ziprasidone)
olanzapine	GEODON IM (ziprasidone)
quetiapine <sup>***</sup> AP for the 25mg Tablet Only	INVEGA (paliperidone)
<b>RISPERDAL CONSTA (risperidone)<sup>CL**</sup></b>	olanzapine IM <sup>**</sup>
risperidone	RISPERDAL (risperidone)
SAPHRIS (asenapine) <sup>AP</sup>	SEROQUEL (quetiapine)
ziprasidone	SEROQUEL XR (quetiapine)
	VERSACLOZ (clozapine)
	ZYPREXA (olanzapine)
	ZYPREXA IM (olanzapine) <sup>**</sup>
	ZYPREXA RELPREVV (olanzapine)

## F. Beta Blockers

Magellan recommended that Inderal XL be moved to non-preferred status. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

BETA BLOCKERS <sup>AP</sup>	
acebutolol	BETAPACE (sotalol)
atenolol	BYSTOLIC (nebivolol)
betaxolol	CORGARD (nadolol)
bisoprolol	INDERAL LA (propranolol)
metoprolol	<b>INDERAL XL (propranolol)</b>
metoprolol ER	INNOPRAN XL (propranolol)
nadolol	KERLONE (betaxolol)
pindolol	LEVATOL (penbutolol)
propranolol	LOPRESSOR (metoprolol)
propranolol ER	SECTRAL (acebutolol)
sotalol	TENORMIN (atenolol)
timolol	TOPROL XL (metoprolol)
	ZEBETA (bisoprolol)

## G. Bladder Relaxant Preparations

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

BLADDER RELAXANT PREPARATIONS <sup>AP</sup>	
oxybutynin IR	DETROL (tolterodine)
oxybutynin ER	DETROL LA (tolterodine)

TOVIAZ (fesoterodine)  
VESICARE (solifenacin)

DITROPAN XL (oxybutynin)  
ENABLEX (darifenacin)  
flavoxate  
GELNIQUE (oxybutynin)  
MYRBETRIQ (mirabegron)  
OXYTROL (oxybutynin)  
SANCTURA (trospium)  
SANCTURA XR (trospium)  
tolterodine  
tolterodine ER  
trospium

## H. Bone Resorption Suppression and Related Agents

Magellan recommended that risedronate be moved to non-preferred status. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### BONE RESORPTION SUPPRESSION AND RELATED AGENTS

#### BISPHOSPHONATES

alendronate tablets

ACTONEL (risedronate)  
ACTONEL WITH CALCIUM (risedronate/ calcium)  
alendronate solution  
ATELVIA (risedronate)  
BINOSTO (alendronate)  
BONIVA (ibandronate)  
DIDRONEL (etidronate)  
etidronate  
FOSAMAX TABLETS (alendronate)  
FOSAMAX PLUS D (alendronate/vitamin D)  
Ibandronate  
risedronate

## I. BPH Treatments

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### BPH TREATMENTS

#### 5-ALPHA-REDUCTASE (5AR) INHIBITORS

finasteride

AVODART (dutasteride)  
CIALIS 5 mg (tadalafil)  
PROSCAR (finasteride)

#### ALPHA BLOCKERS

alfuzosin  
doxazosin  
tamsulosin  
terazosin

CARDURA (doxazosin)  
CARDURA XL (doxazosin)  
FLOMAX (tamsulosin)  
HYTRIN (terazosin)  
RAPAFLO (silodosin)  
UROXATRAL (alfuzosin)

#### 5-ALPHA-REDUCTASE (5AR) INHIBITORS/ALPHA BLOCKER COMBINATION

JALYN (dutasteride/tamsulosin)

## J. COPD Agents

Magellan recommended that Anoro Ellipta be added to non-preferred status. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

<b>COPD AGENTS</b>	
<b>ANTICHOLINERGIC-BETA AGONIST COMBINATIONS<sup>AP</sup></b>	
albuterol/ipratropium COMBIVENT RESPIMAT (albuterol/ipratropium)	ANORO ELLIPTA (umeclidinium/vilanterol) DUONEB (albuterol/ipratropium)

## K. Epinephrine, Self-Injected

Magellan recommended that epinephrine and Auvi-Q be moved to preferred status and Epipen and Epipen Jr. be moved to non-preferred status. The motion to table the decision on this class until the January meeting was made and seconded. A vote was taken and the motion was approved.

<b>EPINEPHRINE, SELF-INJECTED</b>	
EPIPEN (epinephrine) EPIPEN JR (epinephrine)	ADRENALIN (epinephrine) AUVI-Q (epinephrine) epinephrine

## L. Glucocorticoids, Inhaled

Magellan recommended that this class remain unchanged. A motion was made to keep Asmanex and QVAR as the only preferred inhaled glucocorticoids. A vote was taken and the motion was approved by a majority of the Committee.

<b>GLUCOCORTICOIDS, INHALED<sup>AP</sup></b>	
<b>GLUCOCORTICOIDS</b>	
ASMANEX (mometasone) PULMICORT RESPULES (budesonide)* QVAR (beclomethasone)	AEROSPAN (flunisolide) ALVESCO (ciclesonide) budesonide FLOVENT HFA (fluticasone) FLOVENT Diskus (fluticasone) PULMICORT FLEXHALER (budesonide)

## M. Hepatitis B Treatments

Magellan recommended that this class remain unchanged. A Committee member was concerned with the resistance of Epivir HBV. A motion was made to accept the recommendations with the addition of Tyzeka being moved to preferred status. A vote was taken and the motion was approved.

<b>HEPATITIS B TREATMENTS</b>	
EPIVIR HBV (lamivudine) TYZEKA (telbivudine)	Adefovir BARACLUDE (entecavir) HEPSERA (adefovir) lamivudine HBV

## N. Hepatitis C

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### HEPATITIS C TREATMENTS<sup>CL</sup>

PEGASYS (pegylated interferon)	COPEGUS (ribavirin)
PEG-INTRON (pegylated interferon)	INCIVEK (telaprevir)
RIBASPHERE 200mg	INFERGEN (consensus interferon)
ribavirin	OLYSIO (simeprevir)*
	REBETOL (ribavirin)
	RIBAPAK (ribavirin)
	RIBASPHERE 400mg, 600mg (ribavirin)
	ribavirin dose pack
	SOVALDI (sofosbuvir)*
	VICTRELIS (boceprevir)*

## O. Hypoglycemics, Incretin Mimetics/Enhancers

Magellan recommended that Jentadueto be moved to preferred status. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

INJECTABLE	
BYETTA (exenatide) <sup>AP*</sup>	BYDUREON (exenatide)**
VICTOZA (liraglutide) <sup>AP*</sup>	SYMLIN (pramlintide)***
ORAL <sup>AP</sup>	
JANUMET (sitagliptin/metformin) <sup>AP</sup>	JANUMET XR (sitagliptin/metformin)*
JANUVIA (sitagliptin) <sup>AP</sup>	KAZANO (alogliptin/metformin)
<b>JENTADUETO (linagliptin/metformin)</b>	KOMBIGLYZE XR (saxagliptin/metformin) *
TRADJENTA (linagliptin) <sup>AP</sup>	NESINA (alogliptin)
	ONGLYZA (saxagliptin) **
	OSENI (alogliptin/pioglitazone)

## P. Hypoglycemics, Insulin and Related

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

HUMALOG (insulin lispro)	APIDRA (insulin glulisine) <sup>AP</sup>
HUMALOG MIX VIALS (insulin lispro/lispro protamine)	HUMALOG PEN/KWIKPEN (insulin lispro)
HUMULIN VIALS (insulin)	HUMALOG MIX PENS (insulin lispro/lispro protamine)
LANTUS (insulin glargine)	HUMULIN PENS (insulin)
LEVEMIR (insulin detemir)	
NOVOLIN (insulin)	
NOVOLOG (insulin aspart)	
NOVOLOG MIX (insulin aspart/aspart protamine)	

**Q. Hypoglycemics, SGLT2**

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

**HYPOGLYCEMICS, SGLT2**

FARXIGA (dapagliflozin) INVOKANA (canagliflozin)
---

**R. Irritable Bowel Syndrome (New Class for Review)**

Magellan recommended for this new class of Irritable Bowel Syndrome that Amitiza be added with preferred status and Linzess and Lotronex be moved to non-preferred status. A motion was made to accept the recommendations with Linzess being moved to preferred status.

**IRRITABLE BOWEL SYNDROME**

AMITIZA (lubiprostone) <sup>CL*</sup> LINZESS (linaclotide) <sup>CL*</sup>	LOTROXEX (alosetron)
---	----------------------

**S. Laxatives and Cathartics (New Class for Review)**

Magellan recommended for this new class of Laxatives and Cathartics that Colyte, Golytely, Nulytely, and PEG3350 be added with preferred status and Halflytely-Bisacodyl kit, Moviprep, Osmoprep, Prepopik, and Suprep be added with non-preferred status. The motion to approve the recommendation as presented was made and seconded. A vote was taken and the motion was approved.

**LAXATIVES AND CATHARTICS**

COLYTE GOLYTELY NULYTELY peg 3350	HALFLYTELY-BISACODYL KIT MOVIPREP OSMOPREP PREPOPIK SUPREP
--	--

**T. Lipotropics, Statins**

Magellan recommended that Lescol, Lescol XL, Advicor, and Simcor be moved to non-preferred status. A motion was made to accept the recommendations with the addition of Crestor being moved to preferred status and amlodipine/atorvastatin being moved to non-preferred status.

**LIPOTROPICS, STATINS<sup>AP</sup>**

STATINS

atorvastatin <b>CRESTOR (rosuvastatin)</b> lovastatin pravastatin simvastatin <sup>CL*</sup>	ALTOPREV (lovastatin) fluvastatin <b>LESCOL (fluvastatin)</b> <b>LESCOL XL (fluvastatin)</b> LIPITOR (atorvastatin) LIVALO (pitavastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin)*
<b>STATIN COMBINATIONS</b>	
	<b>ADVICOR (lovastatin/niacin)</b> amlodipine/atorvastatin CADUET (atorvastatin/amlodipine) LIPTRUZET (atorvastatin/ezetimibe) <b>SIMCOR (simvastatin/niacin ER)</b> VYTORIN (simvastatin/ezetimibe)

### U. Neuropathic Pain

Magellan recommended that this class remain unchanged. A motion was made to accept the recommendations with the addition of Lidoderm being moved to preferred status. A vote was taken and the motion was approved.

<b>NEUROPATHIC PAIN</b>	
capsaicin OTC duloxetine gabapentin capsules, solution <b>LIDODERM (lidocaine)**</b>	CYMBALTA (duloxetine) gabapentin tablets GRALISE (gabapentin)* HORIZANT (gabapentin) lidocaine patch LYRICA CAPSULE (pregabalin)*** LYRICA SOLUTION (pregabalin)*** NEURONTIN (gabapentin) QUTENZA (capsaicin) SAVELLA (milnacipran)**** ZOSTRIX OTC (capsaicin)

### V. NSAIDs

Magellan recommended that diclofenac solution be moved to non-preferred status. A motion was made to accept the recommendations with the addition of Voltaren gel being moved to preferred status. A vote was taken and the motion was approved.

<b>NSAIDS<sup>AP</sup></b>	
<b>TOPICAL</b>	
<b>VOLTAREN GEL (diclofenac)*</b>	<b>diclofenac solution</b> FLECTOR PATCH (diclofenac) PENNSAID (diclofenac)

### W. Ophthalmics, Anti-Inflammatories-Immunomodulators (New Class for Review)

Magellan recommended for this new class of Ophthalmics, Anti-Inflammatories-Immunomodulators that Restasis be added with non-preferred status. The motion to

approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### OPHTHALMICS, ANTI-INFLAMMATORIES- IMMUNOMODULATORS

RESTASIS (cyclosporine)
-------------------------

### X. Opiate Dependence Treatments

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### OPIATE DEPENDENCE TREATMENTS

SUBOXONE FILM (buprenorphine/naloxone) <sup>CL</sup> VIVITROL (naltrexone) <sup>CL</sup>	SUBOXONE TABLETS (buprenorphine/naloxone) buprenorphine/naloxone tablets ZUBSOLV (buprenorphine/naloxone)
---	---

### Y. Pancreatic Enzymes

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### PANCREATIC ENZYMES<sup>AP</sup>

CREON PANCRELIPASE 5000 ZENPEP	PANCREAZE PERTZYE ULTRESA VIOKACE
--------------------------------------	--

### Z. Ulcerative Colitis

Magellan recommended that this class remain unchanged. The motion to approve the recommendations as presented was made and seconded. A vote was taken and the motion was approved.

### ULCERATIVE COLITIS AGENTS<sup>AP</sup>

ORAL	
APRISO (mesalamine) balsalazide DELZICOL (mesalamine) PENTASA (mesalamine) 250mg sulfasalazine	ASACOL HD (mesalamine) AZULFIDINE (sulfasalazine) COLAZAL (balsalazide) DIPENTUM (olsalazine) GIAZO (balsalazide) LIALDA (mesalamine) PENTASA (mesalamine) 500mg UCERIS (budesonide)
RECTAL	
CANASA (mesalamine) mesalamine	mesalamine kit ROWASA (mesalamine) SF ROWASA (mesalamine)

**XII. Next Meeting**

The next P&T meeting is scheduled for January 28, 2015 at 2PM in the Bureau for Medical Services' offices, Diamond Building, 350 Capitol Street, Charleston, WV.

**XIII. Other Business**

Dr. Matulis asked for nominations for officers of the P&T Committee. Dr. Robert Stanton and Dr. Bradley Henry were nominated for Chair and Vice Chair respectively. The motion was seconded. A vote was taken and the motion was approved.

**XIV. Adjournment**

The meeting was adjourned at 2:01PM.